Drug intelligence / Profile preview

olmesartan medoxomil + hydrochlorothiazide

Development stage
Approved
Lead developer
Daiichi Sankyo Company
Modality
Small Molecules
Administration
Oral
01

Overview

Olmesartan medoxomil + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension). It combines two active ingredients: - Olmesartan medoxomil, an angiotensin II receptor blocker (ARB), which works by selectively blocking the binding of angiotensin II to the Angiotensin II receptor type 1 (AT1) in vascular smooth muscle. This action leads to vasodilation and reduced blood pressure. - Hydrochlorothiazide, a thiazide diuretic that lowers blood pressure by increasing renal excretion of sodium and water. This combination is indicated for patients whose blood pressure is not adequately controlled with olmesartan alone. The drug reduces cardiovascular risks associated with hypertension such as stroke and heart attack. It is administered orally[1][2][5][6].

Brand names
Benicar HCTBenitec H
Other names
olmesartan/hydrochlorothiazideolmesartan medoxomil and hydrochlorothiazide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on olmesartan medoxomil + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on olmesartan medoxomil + hydrochlorothiazide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call